Celyad and Medisun Alter Terms of China Stem Cell Deal

Celyad SA, a Belgium cell therapy company, announced an altered China collaboration with Medisun International of Hong Kong for greater China registration and distribution of  C-Cure ® . C-Cure is a stem cell-based treatment for ischemic heart failure that was developed by Mayo Clinic and licensed by Celyad. Medisun agreed to invest at least $22 million to register the treatment in China. The agreement was originally announced one year ago; now, the two entities have altered its terms. More details.... Stock Symbol: (Euronext: CYAD) Share this with colleagues: // //